Showing results (1161-1170 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|December 19, 2014
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?Vijaya L Damaraju, Michelle Kuzma, Delores Mowles, et al.
Molecular Cancer Therapeutics|December 19, 2014
The use of dipeptide derivatives of 5-aminolaevulinic acid promotes their entry to tumor cells and improves tumor selectivity of photodynamic therapyGabriela Di Venosa, Pablo Vallecorsa, Francesca Giuntini, et al.
Molecular Cancer Therapeutics|December 19, 2014
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modificationsRemi Adelaiye, Eric Ciamporcero, Kiersten Marie Miles, et al.
Molecular Cancer Therapeutics|December 19, 2014
A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancerYouli Pan, Mingwu Zheng, Lei Zhong, et al.
Molecular Cancer Therapeutics|November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancerMelissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Molecular Cancer Therapeutics|November 8, 2014
Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapiesWalter Hans Meisen, Samuel Dubin, Steven T Sizemore, et al.
Molecular Cancer Therapeutics|November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitorAndrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
Molecular Cancer Therapeutics|November 9, 2014
Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signalingNitu Bansal, Nadine Johnson Farley, Lisa Wu, et al.
Molecular Cancer Therapeutics|November 23, 2014
Mechanisms of resistance to cabazitaxelGeorge E Duran, Yan C Wang, E Brian Francisco, et al.
Molecular Cancer Therapeutics|November 23, 2014
TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical modelsShuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka, et al.
Pageof 599